Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma

Area of Science:

• Oncology
• Immunology

Background:

• Metastatic urothelial carcinoma (UC) treatment landscape evolving.
• Cisplatin-based chemotherapy is standard for eligible patients.
• Immunotherapy presents new options for specific patient groups.

Purpose of the Study:

• Review updated clinical efficacy of PD-1/PD-L1 inhibitors in advanced UC.
• Provide guidance on sequencing immunotherapy with chemotherapy.

Main Methods:

• Review of clinical trial data for approved PD-1/PD-L1 inhibitors.
• Analysis of immunotherapy's role in first- and second-line settings.
• Consideration of patient eligibility criteria (cisplatin-ineligible, PD-L1 status).

Main Results:

• Five PD-1/PD-L1 inhibitors (pembrolizumab, atezolizumab, durvalumab, nivolumab, avelumab) approved for metastatic UC.
• Immunotherapy is an option for frontline cisplatin-ineligible patients (chemo-intolerant or PD-L1 positive).
• Immunotherapy is also available in the second-line setting.

Conclusions:

• PD-1/PD-L1 inhibitors represent significant advancements in metastatic UC treatment.
• Strategic sequencing of immunotherapy and chemotherapy is crucial for optimal patient outcomes.
• Further research needed to refine treatment algorithms.